190 related articles for article (PubMed ID: 18685900)
1. Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
Reddy SK; Broadwater G; Niedzwiecki D; Barbas AS; Hurwitz HI; Bendell JC; Morse MA; Clary BM
J Gastrointest Surg; 2009 Jan; 13(1):74-84. PubMed ID: 18685900
[TBL] [Abstract][Full Text] [Related]
2. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
[TBL] [Abstract][Full Text] [Related]
3. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
[TBL] [Abstract][Full Text] [Related]
4. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
5. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
[TBL] [Abstract][Full Text] [Related]
6. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Viganò L; Capussotti L; Barroso E; Nuzzo G; Laurent C; Ijzermans JN; Gigot JF; Figueras J; Gruenberger T; Mirza DF; Elias D; Poston G; Letoublon C; Isoniemi H; Herrera J; Sousa FC; Pardo F; Lucidi V; Popescu I; Adam R
Ann Surg Oncol; 2012 Sep; 19(9):2786-96. PubMed ID: 22622469
[TBL] [Abstract][Full Text] [Related]
7. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Garufi C; Torsello A; Tumolo S; Ettorre GM; Zeuli M; Campanella C; Vennarecci G; Mottolese M; Sperduti I; Cognetti F
Br J Cancer; 2010 Nov; 103(10):1542-7. PubMed ID: 20959822
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
12. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
[TBL] [Abstract][Full Text] [Related]
15. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
[TBL] [Abstract][Full Text] [Related]
16. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
17. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
18. Consequences of chemotherapy on resection of colorectal liver metastases.
Pessaux P; Chenard MP; Bachellier P; Jaeck D
J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
20. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.
Toyama Y; Ushigome T; Watanabe K; Kitamura H; Onda S; Saito R; Yoshida S; Kawahara H; Yanagisawa S; Yanaga K
World J Surg Oncol; 2012 Jun; 10():129. PubMed ID: 22747970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
